Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
D. Ponticelli, Ippazio Cosimo Antonazzo, Grazia Caci, Andrea Vitale, Giovanni Della Ragione, Maria L. Romano, Mario Borrelli, Beniamino Schiavone, Riccardo Polosa, Pietro Ferrara
Abstract
This sero-survey describes the level and time-trend of antibodies elicited by BNT162b2 COVID-19 vaccine up to 6 months. A strong seroconversion was seen at 30-day serology, with persistence of anti-SARS-CoV-2 S-RBD IgG through 6 months from vaccination. However, the level of vaccine-induced antibodies started to decrease from the second month.
Topics & Concepts
MedicineSeroconversionCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SerologyVaccination2019-20 coronavirus outbreakVirologyAntibody responseAntibodyImmunologyImmunogenicityInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesImmunotherapy and Immune Responses